Meeting
2012 ASCO Annual Meeting
Phase II trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) for refractory germ-cell tumors (GCT).
Authors
Yago Nieto
University of Texas M. D. Anderson Cancer Center, Houston, TX
Yago Nieto , Nizar M. Tannir , Shi-Ming Tu , Roy B. Jones , Amado J. Zurita , Ana Aparicio , Roland Bassett Jr., Kim Allyson Margolin , Leona Holmberg , Richard E. Champlin , Lance C. Pagliaro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer
Sub Track
Germ Cell/Testicular
Clinical Trial Registration Number
00936936
Citation
J Clin Oncol 30, 2012 (suppl; abstr 4533)
DOI
10.1200/jco.2012.30.15_suppl.4533
Abstract #
4533
Poster Bd #
12
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase 2 trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) for refractory germ-cell tumors (GCT).
First Author: Yago Nieto
Poster
2017 ASCO Annual Meeting
Infusional gemcitabine + docetaxel/melphalan/carboplatin (GemDMC) ± bevacizumab (BEV) as an effective high-dose chemotherapy (HDC) regimen for refractory of poor-risk relapsed germ-cell tumors (GCT).
First Author: Yago Nieto
Poster
2011 ASCO Annual Meeting
Phase II clinical trial of oxaliplatin and bevacizumab in refractory metastatic germ cell tumors (GCT).
First Author: A. Jain
Poster
2022 ASCO Genitourinary Cancers Symposium
A phase II trial evaluating the efficacy of cabozantinib in the treatment of patients with refractory germ-cell tumors (GCT).
First Author: Jennifer King